Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J.

Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.

PMID:
29496663
2.

Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, Jacobs K, Geerdens E, Gielen O, Soulier J, Harrison CJ, Constantinescu SN, Cools J.

Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.

3.

Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Bornschein S, Demeyer S, Stirparo R, Gielen O, Vicente C, Geerdens E, Ghesquière B, Aerts S, Cools J, de Bock CE.

Leukemia. 2018 Apr;32(4):941-951. doi: 10.1038/leu.2017.328. Epub 2017 Nov 20.

4.

Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.

Dagklis A, Demeyer S, De Bie J, Radaelli E, Pauwels D, Degryse S, Gielen O, Vicente C, Vandepoel R, Geerdens E, Uyttebroeck A, Boeckx N, de Bock CE, Cools J.

Blood. 2016 Dec 8;128(23):2642-2654. Epub 2016 Sep 30.

5.

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L.

J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.

6.

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, Jacobs K, Geerdens E, Gianfelici V, Hulselmans G, Fiers M, Aerts S, Meijerink JP, Tousseyn T, Cools J.

Blood. 2014 Nov 13;124(20):3092-100. doi: 10.1182/blood-2014-04-566687. Epub 2014 Sep 5.

7.

The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.

Noël LA, Arts FA, Montano-Almendras CP, Cox L, Gielen O, Toffalini F, Marbehant CY, Cools J, Demoulin JB.

Mol Oncol. 2014 May;8(3):728-40. doi: 10.1016/j.molonc.2014.02.003. Epub 2014 Feb 17.

8.

NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.

De Keersmaecker K, Porcu M, Cox L, Girardi T, Vandepoel R, de Beeck JO, Gielen O, Mentens N, Bennett KL, Hantschel O.

Haematologica. 2014 Jan;99(1):85-93. doi: 10.3324/haematol.2013.088674. Epub 2013 Jul 19.

9.

Development of a siRNA and shRNA screening system based on a kinase fusion protein.

Pieraets S, Cox L, Gielen O, Cools J.

RNA. 2012 Jun;18(6):1296-306. doi: 10.1261/rna.030015.111. Epub 2012 Apr 26.

10.

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.

Van Roosbroeck K, Cox L, Tousseyn T, Lahortiga I, Gielen O, Cauwelier B, De Paepe P, Verhoef G, Marynen P, Vandenberghe P, De Wolf-Peeters C, Cools J, Wlodarska I.

Blood. 2011 Apr 14;117(15):4056-64. doi: 10.1182/blood-2010-06-291310. Epub 2011 Feb 15.

11.

JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.

Porcu M, Gielen O, Cools J, De Keersmaecker K.

Haematologica. 2009 Mar;94(3):435-7. doi: 10.3324/haematol.13587. Epub 2009 Jan 27. No abstract available.

12.

Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.

De Keersmaecker K, Rocnik JL, Bernad R, Lee BH, Leeman D, Gielen O, Verachtert H, Folens C, Munck S, Marynen P, Fornerod M, Gilliland DG, Cools J.

Mol Cell. 2008 Jul 11;31(1):134-42. doi: 10.1016/j.molcel.2008.05.005.

Supplemental Content

Loading ...
Support Center